tesa Labtec's Rapidfilm® is an innovative oral dosage form that offers strong advantages to patients and combines the convenience of a liquid with the stability and dosing accuracy of a tablet. We offer this technology accompanied by our development and manufacture expertise to our customers.
We like to bring your attention to a recent article published in a leading European Journal which demonstrates the advantage of our oral films in comparison to gold standard applications in paediatric fields:
"Acceptability of an orodispersible film compared to syrup in neonates and infants: a randomized controlled trial”
(Eur. J. Pharm. Biopharm, Volume 151, 2020, P. 239 ff)
V. Klingmann1; C. Pohly1; T. Meissner1; E. Mayatepek1; A. Moeltner2; K. Flunkert3; J. Breitkreutz4; HM. Bosse1
1 Department of General Pediatrics, University Children’s Hospital, Düsseldorf, Germany
2 Center of Excellence for Assessment in Medicine, Heidelberg, Germany
3 M.A.R.C.O. Institute for Clinical Research and Statistics, Düsseldorf, Germany
4 Institute of Pharmaceutics & Biopharmaceutics, Heinrich-Heine-University, Düsseldorf, Germany
You can download the full article here: European Journal of Pharmaceutics and Biopharmaceutics
The orodispersible Rapidfilm® works like a conventional or orodispersible tablet. The film is placed on the tongue and dissolves within a few seconds. The active ingredient is swallowed together with the saliva and takes the same route as a tablet via the liver where the drug is metabolized.
Depending on whether the drug shall become effective within seconds or only after hours, tesa Labtec offers a broad variety of formulation alternatives in order to meet our customer’s individual need. So a fast onset as well as a slow release form of a Rapidfilm can be offered. Since many drugs do not provide a convenient taste, tesa Labtec is also capable in masking the taste of the active ingredient.
Moreover, an oral dissolvable film can also be an attractive dosage form for an already existing product offering the stated advantages and limiting risks and costs for the development of a new Rx or OTC product.